concatenating prescriptions if the gap is less than 30 days (versus) . what is their reference for using 84 days (12 weeks) 2. Page 5 lines [25] [26] [27] What is the assumption behind using 6-month baseline period compared to a 1 year baseline period which enables better assessment of confounders and prevalent/incident users patients.
3. Page 6 lines 18-22 In variable selection, they have used different methods : backward selection and clinical knowledge, I presume, it might be useful if they clarified that better. With all the limitations with model based variable selection, I would go with predefined set of confounders.
4. Page 6 lines 50-52 The bootstrap sampling, 400, seems small for constructing confidence intervals, I would go for a minimum of 1000 bootstraps.
5. Page 6 lines 12-15 -I would add few lines to clarify what discrete time failure models are as opposed to Cox models, the description is very brief and abstract for clinical researchers I believe. It also helps replication of the study using different cohort.
6. Page 7 lines 44-46-Why adjusting for calendar time, have the authors considered if calendar time might be an instrumental variable with risk of bias amplifications if there is any unmeasured bias.
7. Page 8 lines 31-33 _ Prevalent users analysis will only add confounding and shall be removed from sensitivity analysis. 9. Page 10, lines 19-, the cohort included a mix of patients with different inclusion disease which might present confounding by severity of disease and so on. I wouldn't agree the robustness of the study to unmeasured confounding and it is of a concern to me. The fact that adjustment was not made for example to smoking especially in the age group with higher risk.
REVIEWER
Sang-Heng Kok National Taiwan University, Taiwan REVIEW RETURNED 15-May-2017
GENERAL COMMENTS
The manuscript is generally well-written. The topic of oral glucocorticoid use and osteonecrosis is clinically relevant and the methodology employed in the study is sound. Although limitations exist for this type of population-based retrospective analysis, the results obtained do provide new information on glucocorticoidrelated osteonecrosis.
VERSION 1 -AUTHOR RESPONSE
Major: 1. I do agree with the authors that Oral glucocorticosteroid use may not be protective of osteonecrosis but evidence in both direction is limited, therefore, i would consider a two sided test which would allow to test effect in both sides specially children with out any loss of continuity. [e.g., refs 4-9,12,13,25,35-37,40-43] ) as well as clinical trials [e.g., PMID 12070007, 22901620, 23358966] 
Further, given statistical power in children is one of the potential weaknesses of the study, a 90% CI gives us more power. We did not find an increased risk of osteonecrosis in glucocorticoid-exposed children even though the 90% CI is the more conservative analysis. This key finding (including the point estimates of our analyses) would not change with a two-sided approach:
Original analysis: 1-sided testing, 90% CI Ages 2-9 1.1 (0.7, 1.7) Ages 10-17 0.6 (0.3, 1.6) Ages 18-49 2.1 (1.5, 2.9) Ages ≥50 1.3 (1.01, 1.7)
Alternative analysis: 2-sided testing, 95% CI Ages 2-9 1.1 (0.7, 1.8) Ages 10-17 0.6 (0.2, 1.8) Ages 18-49 2.1 (1.4 3.1) Ages ≥50 1.3 (0.96, 1.8)
For the above reasons, we would much prefer to keep our analyses consistent with our a priori plan of one-sided hypothesis testing. If, however, the editors prefer, we would redo our analyses using 2-sided hypothesis testing.
2. I would do the multiple imputation analysis as a main outcome as opposed to a sensitivity analysis as the contribution of smoking, alcohol consumption and life style factors to osteoporosis is not evaluated.
We thank the reviewer for this suggestion and agree that additional factors, measured and unmeasured, could have confounded our results. We would note, however, that the analyses using multiple imputation (with alcohol and socioeconomic information) yielded estimates and confidence intervals nearly identical to the primary analyses; the addition of these variables did not change the results in any way.
Original analysis: no imputed variables Ages 2-9 1.1 (0.7, 1.7) Ages 10-17 0.6 (0.3, 1.6) Ages 18-49 2.1 (1.5, 2.9) Ages ≥50 1.3 (1.01, 1.7)
Alternative analysis: with multiply imputed alcohol, Townsend deprivation index Ages 2-9 1.1 (0.7, 1.7) Ages 10-17 0.7 (0.3, 1.6) Ages 18-49 2.1 (1.5, 2.9) Ages ≥50 1.3 (1.01, 1.7)
Tobacco was not included in our multiple imputation models because, though it was a variable with considerable missingness, we did not consider it a likely confounder a priori. The addition of smoking as an independent variable (including a level for missing values) to the main regression model did not change the results:
Original analysis: without adjustment for smoking Ages 2-9 1.1 (0.7, 1.7) Ages 10-17 0.6 (0.3, 1.6) Ages 18-49 2.1 (1.5, 2.9) Ages ≥50 1.3 (1.01, 1.7)
Alternative analysis: with adjustment for smoking Ages 2-9 1.1 (0.7, 1.7) Ages 10-17 0.7 (0.3, 1.6) Ages 18-49 2.1 (1.5, 2.9) Ages ≥50 1. 3. It would be great of the authors motivated why the age group >50 is not split in to two groups as there seems to be enough number of patients and may not have power issues unless they assume that the disease pathophysiology is the same after the age of 50 which I would not agree. 2. Page 5 lines 25-27 What is the assumption behind using 6-month baseline period compared to a 1 year baseline period which enables better assessment of confounders and prevalent/incident users patients. [e.g., PMID 18494836, 21749853, 23221331, 20682680, 16645966] . Of note, 56% of subjects in our study were registered before the 6-month baseline period in practices with prior electronic data collection. These subjects had a median of 7 years (IQR 4, 10) We used resampling methods to generate confidence intervals, bootstrapping across 400 iterations, a number based on prior methodologic and applied studies. (refs 35, 36) [p7] 5. Page 6 lines 12-15 -I would add few lines to clarify what discrete time failure models are as opposed to Cox models, the description is very brief and abstract for clinical researchers I believe. It also helps replication of the study using different cohort.
